J&J deepens its Canada ties with $690M in R&D deals

Damian Garde Johnson & Johnson's new R&D outpost in Toronto isn't slated to open until the spring, but the company has already inked a pair of collaboration deals worth ...

Zafgen finally breaks its silence, says it’s probing death of a patient

John Carroll More than two days after Zafgen's stock started to get crushed under the heavy weight of speculation surrounding its sudden decision to cancel a roadshow presentation ...

Allergan plots 117 job cuts in the wake of Kythera buyout

Tracy Staton The job-cutting ax has been hovering over Kythera Biopharmaceuticals ever since Allergan agreed to buy the company in April. Now, that ax is getting ready to fall. FiercePharma ...

The FDA is lukewarm on those hyper-valuable vouchers for fast drug reviews

Damian Garde Big Pharma has been willing to pay hundreds of millions of dollars for a shortcut to FDA approval, buying up priority review vouchers created to incentivize new drugs for ...

U.K. cost gatekeeper says ‘OK’ to Merck’s Keytruda for advanced skin cancer

Emily Wasserman Merck's Keytruda got a green light from the U.K.'s cost effectiveness gatekeeper to treat patients with advanced skin cancer, chalking up another victory as ...

FDA puts off its decision on Newron’s Parkinson’s drug

Damian Garde Italian biotech Newron Pharmaceuticals will have to wait another three months for a final FDA decision on its investigational Parkinson's treatment. FierceBiotech News

UPDATED: Novartis falls short in controversial IPR process as board nixes Gilenya patent

Tracy Staton The U.S. Patent and Trademark Office's review board has dealt its first blow to Big Pharma. The appeal panel nixed a patent on Novartis' multiple sclerosis blockbuster ...
Page 3 of 3123
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS